Stocktoria
PROVECTUS BIOPHARMACEUTICALS, INC. PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $336,108 | $617,140 | $557,710 | $989,042 | — | — | — | — | — | — |
| R&D expense | $1.9M | $2.1M | $1.7M | $2.4M | $2.6M | $2.8M | $4.0M | $4.7M | $8.2M | $8.2M |
| Operating income | -$5.3M | -$4.5M | -$2.9M | -$3.4M | -$4.7M | -$5.0M | -$6.3M | -$8.1M | -$13.3M | -$24.5M |
| Interest expense | $5,338 | $13,591 | $5,650 | $3,409 | $961,702 | $1.7M | $1.5M | $969,715 | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | $0 |
| Net income | -$5.4M | -$4.7M | -$3.1M | -$3.6M | -$5.5M | -$6.7M | -$6.9M | -$8.2M | -$13.5M | -$24.4M |
| EPS (diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | — | — | — | — | — | — |
| Operating cash flow | -$3.3M | -$3.3M | -$2.6M | -$3.0M | -$1.0M | -$4.1M | -$6.2M | -$5.2M | -$10.3M | -$21.9M |
| Free cash flow | — | — | — | — | — | — | — | — | -$10.4M | — |
| Cash & equivalents | $251,291 | $307,442 | $76,576 | $21,605 | $682,984 | $97,231 | $590,706 | $50,986 | $105,504 | $1.2M |
| Total assets | $697,502 | $1.0M | $1.4M | $2.0M | $3.5M | $589,201 | $1.5M | $2.0M | $3.4M | $5.6M |
| Total liabilities | $7.0M | $7.0M | $9.0M | $8.3M | $7.7M | $30.8M | $25.5M | $19.4M | $13.5M | $2.1M |
| Shareholders' equity | -$6.3M | -$6.0M | -$7.6M | -$6.2M | -$4.2M | -$30.2M | -$24.1M | -$17.4M | -$10.0M | $3.5M |
Growth · year-over-year · Revenue CAGR -30.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -45.5% | +10.7% | -43.6% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.